Inventiva to Present Corporate Overview at the Cowen and Company 39th Annual Health Care Conference 6 March 2019
The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI 5 March 2019
Inventiva Announces Poster Presentation on a Promising Biomarker for MPS VI at the 15th International Symposium on MPS and Related Diseases 26 July 2018
Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients 26 February 2018
Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI 3 January 2018
Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency 29 August 2017
Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference 29 June 2017
